Trim17（Tripartite motif 17）属于RING型E3泛素连接酶的亚家族，在调节多种细胞过程和病理条件，包括癌症方面发挥作用。然而，它在胃癌（GC）中的潜在功能尚不明确。在这里，我们发现与正常标本相比，人类GC中TRIM17的mRNA和蛋白质水平都上调，TRIM17的上调表明GC患者存活率较低。在功能上，我们发现TRIM17通过促进GC细胞系AGS和HGC-27的增殖和存活来作为一个癌基因起作用。在机制上，TRIM17与BAX相互作用并促进其泛素化和蛋白酶降解，导致无论是否存在凋亡刺激，GC细胞中都存在BAX依赖性凋亡的缺陷。此外，TRIM17和BAX的表达水平在人类GC标本中呈负相关。我们的数据表明，TRIM17通过调控BAX蛋白稳定性并抗凋亡作用来促进胃癌的存活，从而为胃癌治疗提供了一个有希望的治疗靶点和预后生物标志物。© 2023. 作者，ADMCAssociazione Differenziamento e Morte Cellulare的专有许可。

Tripartite motif 17 (TRIM17) belongs to a subfamily of the RING-type E3 ubiquitin ligases, and regulates several cellular processes and pathological conditions including cancer. However, its potential function in gastric cancer (GC) remains obscure. Here, we have found TRIM17 mRNA and protein levels are both upregulated in human GC compared with normal specimens, and TRIM17 upregulation indicates poor survival for GC patients. Functionally, TRIM17 was found to act as an oncogene by promoting the proliferation and survival of GC cell lines AGS and HGC-27. Mechanistically, TRIM17 acts to interact with BAX and promote its ubiquitination and proteasomal degradation, leading to a deficiency in BAX-dependent apoptosis in GC cells in the absence and presence of apoptosis stimuli. Moreover, TRIM17 and BAX expression levels are inversely correlated in human GC specimens. Our data thus suggest TRIM17 contributes to gastric cancer survival through regulating BAX protein stability and antagonizing apoptosis, which provides a promising therapeutic target for GC treatment and a biomarker for prognosis.© 2023. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.